11:31 AM
 | 
Jul 12, 2018
 |  BC Extra  |  Company News

GSK hands off dermatitis, psoriasis candidate to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to receive global rights to atopic dermatitis and psoriasis candidate tapinarof (GSK2894512, WBI-1001). The deal excludes China and is expected to close this half....

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >